Compare OGI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | ENTX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.5M | 147.4M |
| IPO Year | 2015 | 2015 |
| Metric | OGI | ENTX |
|---|---|---|
| Price | $0.88 | $3.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.44 | ★ $9.75 |
| AVG Volume (30 Days) | 414.5K | ★ 548.6K |
| Earning Date | 12-15-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | $34.95 | N/A |
| Revenue Next Year | $30.97 | N/A |
| P/E Ratio | ★ $13.91 | $14.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $0.91 |
| 52 Week High | $2.24 | $4.20 |
| Indicator | OGI | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.55 | 58.75 |
| Support Level | N/A | $2.64 |
| Resistance Level | $0.96 | $3.26 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 11.97 | 74.00 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.